Obtain Recognition of your expertise in Pediatric Urology through the Royal College of Physicians and Surgeons of Canada
The Royal College of Physicians and Surgeons of Canada (RCPSC) has recognized the Area of Focused Competence (AFC) in Pediatric Urology as a Royal College discipline, and has launched a Practice Eligibility Route for this area of focused competence (PER-AFC).
If you would like to have your competencies in Pediatric Urology recognized by the Royal College with an additional designation, we invite you to apply. Eligibility criteria are outlined in the application form, which can be requested at email@example.com.
This application process reviews your discipline specific scope of practice and collects feedback from a number of peers through multisource feedback. Your application will be reviewed by the AFC committee in Pediatric Urology to determine whether you meet the discipline’s requirements. The application fee is $1950 CDN and the annual fee for Diplomates is $250 CDN.
More information regarding the route and application process is available on the Royal College website: Practice Eligibility Route - AFC: The Royal College of Physicians and Surgeons of Canada
Andrew E MacNeily MD FRCSC
Chair, AFC Pediatric Urology Committee
As an ongoing commitment to openness and transparency, Health Canada would like to notify you that a summary safety review (SSR) regarding standard synthetic mid-urethral slings and their long-term safety and effectiveness will be published (see attached document). The SSR is intended to provide Canadians with a sufficient understanding of the safety review conducted by Health Canada, specifically what was assessed, what was found and what action was taken.
Canadian Agency for Drugs and Technologies in Health (CADTH), Canadian Drug Expert Committee (CDEC) and the Institut national d'excellence en santé et services sociaux (INESSS) have recommended PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection) for public reimbursement for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and meet certain conditions.
PLUVICTO™ was approved by Health Canada in August 2022 as a targeted radioligand therapy for the treatment of PSMA-positive mCRPC in Canada1.
For additional information:
CUA-developed clinical tools are all available just one click away on:
TO: Physicians Prescribing Treatment for Non-muscle Invasive Bladder Cancer (NMIBC)
The Medical Advisory Board of Bladder Cancer Canada, with endorsement by the Canadian Urological Association (2021), has reviewed and support the following suggestions. Click "READ MORE" for full details.
AbbVie is pleased to inform you that all formulations of LUPRON DEPOT are now available. More importantly, the inventory shortage which affected the availability of LUPRON DEPOT has now been completely resolved. We do not foresee any future disruptions.
Blayne Welk, Duane Hickling, Greg Bailly, Stephen Steele, Richard Baverstock, Jacques Corcos, Kevin Carlson
The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.
For comments or information, email Corporate.firstname.lastname@example.org